Resources Repository
-
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Cost-Effectiveness Analysis | Health Systems | Health Outcomes | State-Transition | Dynamic Transmission | Microsimulation | Infectious Diseases | Child/Nutrition | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2017OOP Expenditures for Cardiovascular Disease
This article, published in BMJ Global Health, aims to estimate the magnitude and intensity of …
This article, published in BMJ Global Health, aims to estimate the magnitude and intensity of catastrophic health expenditure (CHE) and factors associated with CHE for the prevention and treatment of cardiovascular disease in hospitals in Addis Ababa. Seeking prevention and treatment services for cardiovascular disease in Addis Ababa was found to pose substantial financial burden on households, affecting the poorest and those who reside outside Addis Ababa more. Economic and geographic inequalities should therefore be…
Cost-Effectiveness Analysis | Health Systems | Chronic Disease/Risk | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2016Funding Gap for Immunization Across 94 Low- and Middle-Income Countries
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 …
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 low- and middle-income countries over the five-year period of 2016–2020. Vaccine financing by country governments, GAVI, and other development sources was forecasted for vaccine, supply chain, and service delivery based on an analysis of comprehensive multi-year plans together with a series of scenarios. The authors found that that delivery of full vaccination programs across the 94 countries would result in a total…
Cost-Effectiveness Analysis | Health Systems | Costing Methods | Mathematical Models | Infectious Diseases | Global Governance | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Reproductive, Maternal, Newborn, and Child Health: Key Messages from DCP3
As part of the Disease Control Priorities, Third Edition, the World Bank has published a …
As part of the Disease Control Priorities, Third Edition, the World Bank has published a volume on Reproductive, Maternal, Newborn and Child Health that identifies essential cost-effective health interventions that can be scaled-up now to reduce maternal, newborn and child deaths, and stillbirths. This article summarizes the key findings and estimates the impact and cost of expanded implementation of these interventions. Scaling up all preventive and therapeutic health interventions in these integrated packages from current…
Cost-Effectiveness Analysis | Health Systems | Costing Methods | Maternal/Reproductive Health | Child/Nutrition | Health/Medicine | Global -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Cost-Effectiveness Analysis | Health Systems | Mathematical Models | Dynamic Transmission | Infectious Diseases | Child/Nutrition | Global Governance | Climate/Environment | Economics/Finance | Health/Medicine | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Costs and Benefits of Integrated RMNCH
This chapter assesses the costs and benefits of delivering a set of integrated reproductive, maternal, …
This chapter assesses the costs and benefits of delivering a set of integrated reproductive, maternal, newborn and child health interventions in countries with high child and maternal mortality to demonstrate that very high returns can be achieved through this investment and to underscore the importance of an accurate assessment of those returns. This includes the full range of costs involved in delivering integrated care and the full range of benefits that flow from the interventions.…
Priority Setting/Ethics | Health Systems | Costing Methods | Maternal/Reproductive Health | Child/Nutrition | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2016Prevention and Treatment of Cardiovascular Disease
This article, published in Cost Effectiveness and Resource Allocation, aims to assess the cost-effectiveness of …
This article, published in Cost Effectiveness and Resource Allocation, aims to assess the cost-effectiveness of prevention and treatment of ischemic heart disease (IHD) and stroke in an Ethiopian setting. Fifteen single interventions and sixteen intervention packages are assessed from a healthcare provider perspective. The results indicate that the escalating burden of CVD and its risk factors warrants timely action. Selected CVD intervention packages could be scaled up at a modest budget increase, but the level…
Cost-Effectiveness Analysis | Health Systems | Chronic Disease/Risk | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2016Essential Package of Cancer Control: Costs, Affordability, and Feasibility of an Essential Package of Cancer Control Interventions in LMIC Countries
Investments in cancer control-prevention, detection, diagnosis, surgery, palliative care-are needed in low-income and particularly in …
Investments in cancer control-prevention, detection, diagnosis, surgery, palliative care-are needed in low-income and particularly in middle-income countries, where most of the world's cancer deaths occur without treatment or palliation. To help countries expand locally appropriate services, Disease Control Priorities, 3rd edition developed an essential package of potentially cost-effective measures for countries to consider and adapt. Interventions included in the package are: prevention of tobacco-related cancer and virus-related liver and cervical cancers; diagnosis and treatment of…
Cost-Effectiveness Analysis | Health Systems | Costing Methods | Chronic Disease/Risk | Health/Medicine | Science/Technology | Global -
ArticlePublication 2016Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to …
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to the health service provider. Effective approaches to increase the implementation of guidance are needed. Since investment in activities that improve implementation competes for funding against other health generating interventions, it should be assessed in term of its costs and benefits. In 2010, the National Institute for Health and Care Excellence released a clinical guideline recommending natriuretic peptide (NP) testing in…
Cost-Effectiveness Analysis | Health Systems | Health Outcomes | Operations Research | Chronic Disease/Risk | Clinical Care | Economics/Finance | Health/Medicine | Europe